MedTech Dive June 23, 2021
Dive Brief:
- PerkinElmer and Qiagen are the latest medtechs to target the rapidly growing CRISPR market with technologies designed to aid gene editing to correct genetic defects and treat cancer, hemophilia, sickle cell anemia and other diseases.
- Qiagen has launched new CRISPR products to enable researchers to better analyze the gene editing impact of their work, while PerkinElmer has bought German viral vector gene delivery company SIRION Biotech to complement its portfolio of CRISPR gene editing tools.
- The market for gene therapies has boomed as dozens of companies have advanced deep into clinical testing and several treatments have won regulatory approval. Gene editing is a comparatively smaller market, but growing rapidly as CRISPR and other technologies become important...
Today's Sponsors
Today's Sponsor